TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06562296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion-Intermediate-Chorion
Description: Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion-Intermediate-Chorion
Description: Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion-Chorion-Amnion
Description: Dehydrated human placental trilayer allograft derived from donated human tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion-Chorion-Amnion
Description: Dehydrated human placental trilayer allograft derived from donated human tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
Study: NCT06272448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation...), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
Study: NCT04318002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
Study: NCT06033703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical administration of Netarsudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical administration of Netarsudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical administration of Netarsudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical administration of Netarsudil
Study: NCT05268588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE intervention
Description: group mHealth education and social support intervention
Study: NCT05019716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET-CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study: NCT06283771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated socks to be developed with wearable technology
Description: The study group will wear heated socks to be developed with wearable technology
Study: NCT05875974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP258 (XYWAV)
Description: Initiate dosage per study protocol and titrate to variable dosage.
Study: NCT05472623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adagrasib
Description: Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Adagrasib/Nivolumab
Description: Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
Study: NCT06009432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
Study: NCT06466187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08052666
Description: Given into the vein (IV; intravenously)
Study: NCT04918810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel intermittent
Description: After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
Study: NCT03961945

Intervention type: DEVICE
Group type: OTHER
Intervention: Sponge Capsule
Description: Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sponge Capsule
Description: Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sponge Capsule
Description: Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
Study: NCT06406231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparing efficacy of TENS and PEMF in knee osteoarthritis
Description: Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparing efficacy of TENS and PEMF in knee osteoarthritis
Description: Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups.
Study: NCT05216328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol Only Product in Oral Dose Form
Description: Information already included in arm/group description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium hydroxide 724mg
Description: Information already included in arm/group description.
Study: NCT05686317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards APTURE transcatheter shunt system
Description: Treatment with APTURE shunt

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: CS angiography
Study: NCT05705531

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Undergo medical record abstraction

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05947799

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline questionnaires
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline questionnaires
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline questionnaires
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline questionnaires
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-questionnaire
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-questionnaire
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-questionnaire
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-questionnaire
Description: Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
Study: NCT05111626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Bemarituzumab will be administered as intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Bemarituzumab will be administered as intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IV infusion.
Study: NCT05635773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Alexa Visual Cognitive aid
Description: The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Alexa Visual Cognitive aid
Description: The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
Study: NCT06502314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management training
Description: It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~.
Study: NCT06388018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT05091879

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Multigene pharmacogenomics test
Description: This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Study: NCT06388018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Vaginal Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose-Rate Vaginal Brachytherapy
Description: Undergo vaginal brachytherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05613920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet management program based on the nudge strategy
Description: The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
Study: NCT00864409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0,2%
Description: Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline.9%
Description: Wound infiltration with 170 mL sterile saline
Study: NCT06045429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oroxid®
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine
Study: NCT06388018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04556682

Intervention type: DEVICE
Intervention: Rotational atherectomy
Description: Device used for severely calcified coronary lesion preparation before stent implantation.

Intervention type: DEVICE
Intervention: Intravascular lithotripsy
Description: Device used for severely calcified coronary lesion preparation before stent implantation.
Study: NCT06370546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity
Description: Low intensity group: participants will be requested to perform the following exercises: 1)squat, 2) rowing, 3)deadlift and 4)bench press. All exercises will be performed with low intensity (55% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity
Description: High intensity group: participants will be requested to perform the following exercises: 1)squat, 2)rowing, 3)deadlift and 4)bench press. All exercises will be performed with high intensity (80% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
Study: NCT06388018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT05063344

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx Syphilis Test
Description: For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx Syphilis Test
Description: For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.

Intervention type: DEVICE
Intervention: Diagnostic Test: NOWDx Syphilis Test
Description: For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.